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OBJECTIVES: Grass pollen induced allergic rhinoconjunctivitis (ARC) constitutes a
large burden for the society. The prevalence is increasing and up to 20% of the
European and US populations suffer from respiratory allergies including grass pol-
len induced ARC. The majority of patients are treated with symptomatic medica-
tions; however a large proportion remains uncontrolled despite the use of such
treatments. Specific immunotherapy (SIT) is the only treatment documented to
target the underlying cause of the allergic disease leading to a sustained effect after
treatment completion. The aim of this study was to compare the economic conse-
quences of treatment of patients with ARC with a grass allergy immunotherapy
tablet (AIT) and the clinical practice of subcutaneous immunotherapy (SCIT).
METHODS: A cost-minimisation analysis (CMA) was applied comparing the SQ-
standardised grass AIT (Grazax, Phleum pratense, 75,000 SQ-T/2,800 BAU, ALK,
Denmark) with SCIT (Alutard, Phleum pratense, 100,000 SQ-U/ml, ALK, Denmark).
The CMA included health care utilisation measured in physical units based on
national guidelines, literature reviews and expert opinions, as well as valuation in
unit costs based on drug tariffs, physician fee structures and wage statistics. The
CMA was conducted from a Danish societal and health care perspective. RESULTS:
Treating patients with ARC with the grass AIT instead of grass SCIT results in a
significantly reduced number of physician visits leading to a total reduction in
direct treatment costs, direct patient costs as well as in indirect costs of €3526 per
patient during a treatment course. A one-way sensitivity analysis confirmed the
robustness of these results. CONCLUSIONS: The cost minimisation analyse shows
that grass AIT is a cost-saving alternative to SCIT when treating patients suffering
from grass pollen induced ARC.
PRS11
BUDGET IMPACT ANALYSIS OF IMMUNOTHERAPY IN PATIENTS WITH BIRCH
ALLERGIC RHINITIS
Westerhout KY1, Verheggen BG1, Schreder CH2, Doering C2, Reich K3
1Pharmerit International, Rotterdam, The Netherlands, 2Stallergenes GmbH, Kamp-Lintfort,
Germany, 3Dermatologikum Hamburg, Hamburg, Germany
OBJECTIVES: A budget impact analysis was conducted to estimate the impact of
Staloral Birch® on a market of selected number of relevant birch allergens.
METHODS: The hypothetical market for birch allergens consisted of 3 compounds;
Staloral Birch®, ALK Depot SQ® and SLITone®. Randomized controlled trials have
been performed to estimate safety and efficacy of Staloral Birch® and ALK Depot
SQ®; however, for SLITone® no comparable evidence-based information is avail-
able. Actual German market data from 2008-2010 served as a basis for future esti-
mates of market share development. Future predictions were made on market
uptake and market dynamics (i.e. which drug increases their market share at the
expense of another drug). German drug acquisition costs were taken from the
Lauer-Taxe; average annual treatment related costs have been extracted from a
recent cost-effectiveness analysis for grass allergens. The analysis perspective was
that of the German payer (i.e. Statutory Health Insurance). Three different scenario
analyses were conducted over a 5-year time horizon. RESULTS: The total market
budget in 2010 for these 3 therapies was estimated to be € 36,485,362. It decreased
with €2,263,694 over a 5-year period in the first scenario, when the annual uptake of
Staloral Birch® was set at 6.9% with market dynamics of 80%/20% (ALK Depot
SQ®/SLITone®). These savings represent 1.2% of the cumulative reference budget
varying from 0.4% in 2011 to 2.1% in 2015. In the second scenario market uptake for
Staloral Birch® was varied from2% to8% annually. Accordingly, the budget was
reduced by €656,143 to €2,624,573. In the final scenario, shifting market dynamics
from 90%/10% to 70%/30% (ALK Depot SQ®/SLITone ®) showed a reduction of
€136,675 to €4,390,713.CONCLUSIONS: Increasing Staloral Birch® market share was
estimated to result in a stable, if not decreasing budget with more patients treated
using an evidence-based compound.
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OBJECTIVES: To assess the economic impact of introducing beclomethasone/for-
moterol extrafine for the treatment of moderate to severe persistent asthma in six
Spanish regions including Andalusia, Bask Country, Catalonia, Galicia, Madrid and
Valencia. METHODS: A budget impact model was developed using the perspective
of the Spanish regional healthcare services with a 5-year time horizon. The model
was populated with regional data on disease prevalence, population growth, drug
tariffs, healthcare resource utilization, unit costs and market shares. Drugs con-
sidered in the study were fluticasone/salmeterol, budesonide/formoterol and be-
clomethasone/formoterol extrafine. Costs considered included drug costs, diag-
nostic tests, physician visits, hospitalisation and adverse effects treatment costs.
All costs referred to EUR 2010, using a 5% annual discount rate. Total annual health-
care costs were estimated based on mean costs per patient for each treatment
before and after the introduction of beclomethasone/formoterol extrafine.
RESULTS: Based upon the Spanish adult population data and asthma prevalence,
the treated population with moderate to severe persistent asthma in 2010 was
estimated at 110,346 in Andalusia, at 16,369 in the Bask Country, at 31,118 in Cata-
lonia, at 30,506 in Galicia, at 21,800 in Madrid and at 37,316 in Valencia versus
populations of 140,684, 19,893, 38,378, 37,753, 27,660 and 46,789 respectively in
2015. The annual mean cost per patient was €996 before the introduction of beclo-
methasone/formoterol extrafine and €990 after its introduction. Total annual
health care costs over the next 5 years for all six regions range between €95,7 and
€661,6 million for the Bask Country and Andalucia before the introduction of be-
clomethasone/formoterol extrafine and €95,1 and €657,9 million after its introduc-
tion, respectively.CONCLUSIONS:The introduction of beclomethasone/formoterol
extrafine for the treatment of moderate to severe persistent asthma showed to
reduce the budget impact for each of the regional health care services by showing
net savings for all six regions over the next 5 years.
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OBJECTIVES: Specific immunotherapy (SIT) is the only potentially curative therapy
in patients with allergic rhinitis (AR) and allergic asthma (AA). The present study
examined the effects of specific immunotherapy (SIT) on the financial situation of
the German statutory health insurance systems (SHI). METHODS: Taking popula-
tion projections of the German Statistical Federal Office, the number of expected
new cases (AR, AA) was calculated until 2050. Based on assumptions about the
proportion of patients who received SIT in the future, age cohorts passed cost-
effectiveness models that were based on Markov chains. For determining the cost
situation of SIT remedies, we used selling prices for Allergovit® depot suspensions.
All future costs are discounted at a rate of 2%. Data on effectiveness were extracted
from published literature. The model calculation was supplemented by a Delphi
panel and additional probabilistic sensitivity analysis. RESULTS: Based on the cur-
rent situation, a total annual economic burden of € 1 billion is expected for care of
patients with pollen-induced AR and AA in Germany. Several realistic scenarios
have shown, that despite higher initial expenses, savings of up to 10% of the aver-
age total annual cost are realizable. That would mainly driven by a reduced number
of patients suffering from AA. The size of this cost reduction is mainly affected by
the starting point of therapy: If SIT is applied at an early disease stage without
asthma symptoms, the expected number of asthma sufferers is up to 35% lower
compared to status quo. CONCLUSIONS: From the perspective of statutory health
insurance companies, SIT could be a useful strategic option to prevent future al-
lergic disease cases and to reduce associated medical expenses.
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OBJECTIVES:To estimate the budget impact of introducing indacaterol in the treat-
ment of COPD over a 5-year time horizon in patients eligible for treatment with
long-acting maintenance therapy. METHODS: An Excel-based budget impact
model was developed to calculate the budget impact based on local epidemiologi-
cal and drug costs data. The number of patients eligible for treatment with long-
acting maintenance therapy was estimated considering: 1) the local adult popula-
tion (40 years old) of approximately 14.5 millions; 2) proportion of population
using the public healthcare system services and medications around 77%; 3) prev-
alence of local COPD patients about 15.8%; 4) 18% of these patients are diagnosed
and receiving treatment; 5) 1.05% of annual population growth rate; 6) the same
patient distribution in each disease severity across all years was assumed as 64% of
mild, 29% of moderate, 6% of severe and 1% of very severe; 7) only patients in
moderate, severe and very severe groups were considered as eligible for treatment
with long-acting maintenance therapy; and 8) 53% of annual treatment persistence
rate was applied. The ex-factory price with 24.38% of discount was used for inda-
caterol costs and 5% of annual discount rate was applied on the costs. Indacaterol
150g uptake was assumed to be: 10%, 15%, 20%, 23%, 25%, over 5 years
consecutively. RESULTS: The number of patients eligible for treatment with long-
acting maintenance therapy in São Paulo was estimated to be around 60,754 in the
first year. The annual net budget impact of indacaterol was negative through the
years around: -88K, -1.7M, -3.2M, -4.2M and -4.4M (BRL) consecutively.
CONCLUSIONS: The budget impact results show that indacaterol has potential to
reduce costs on the budget of State health care system.
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OBJECTIVES:To estimate the budget impact of introducing indacaterol in the treat-
ment of COPD over a 5-year time horizon in patients eligible for treatment with
long-acting maintenance therapy. METHODS: An Excel-based budget impact
model was developed to calculate the budget impact based on local epidemiologi-
cal and drug costs data. The number of patients eligible for treatment with long-
acting maintenance therapy was estimated considering: 1) the local adult popula-
tion (40 years old) of approximately 61 millions; 2) proportion of population using
the public healthcare system services and medications around 77%; 3) prevalence
of local COPD patients about 15.8%; 4) 18% of these patients are diagnosed and
receiving treatment; 5) 1.05% of annual population growth rate; 6) the same patient
distribution in each disease severity across all years was assumed as 64% of mild,
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29% of moderate, 6% of severe and 1% of very severe; 7) only patients in moderate,
severe and very severe groups were considered as eligible for treatment with long-
acting maintenance therapy; and 8) 53% of annual treatment persistence rate was
applied. The ex-factory price with 24.38% of discount was used for indacaterol costs
and 5% of annual discount rate was applied on the costs. Indacaterol 150g uptake
was assumed to be: 9%, 13%, 17%, 19%, 21%; and for indacaterol 300g: 1%, 2%, 3%,
4%, 4%, over 5 years consecutively. RESULTS: The number of patients eligible for
treatment with long-acting maintenance therapy in Brazil was estimated to be
around 256,040 in the first year. The annual budget impact of indacaterol through
the years was approximately: 20M, 30M, 38M, 42M and 44M (BRL) consecutively.
CONCLUSIONS: Currently none drugs are reimbursed for COPD maintenance ther-
apy by SUS. According to this analysis, considering only the costs with indacaterol,
it should have a small impact on the Ministry of Health’s budget.
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OBJECTIVES: To assess the health care resources used and estimate the costs as-
sociated with the use of a collagen sponge coated with human fibrinogen and
thrombin compared with fibrin sealant to improve haemostasis in lung surgery and
liver resection. METHODS: A cost-analysis of the healthcare resources used with
the administration of a fibrin-based sponge and fibrin sealant was performed.
Health care resource utilisation and unit costs associated with both treatments in
lung surgery and liver resection was obtained from literature research. Costs in-
cluded for lung surgery were drug costs, preparation and administration time and
additional hospitalisation due to post-surgery pulmonary air leakage. Costs for
liver resection included drug costs, preparation and administration time, drainage
and hospitalisation days at ward or an intensive care unit. Drug costs were ob-
tained from Spanish medication databases. All costs were referred to EUR 2010.
Based on the healthcare resource use the mean cost per patient for each treatment
was estimated. A two-way sensitivity analysis was performed determining mini-
mum and maximum mean costs per patient. RESULTS: Mean drug costs for the
fibrin-based sponge and fibrin sealant in lung surgery resulted in €275 and €345,
respectively. Total treatment costs per patient were estimated at €376 and at €509
for the fibrin-based sponge and fibrin sealant. In liver resection mean drug costs
resulted in €550 for the fibrin-based sponge and in €690 for fibrin sealant, respec-
tively. The associated total treatment costs per patient added up to approximately
€5725 for the fibrin-based sponge and €6148 for fibrin sealant. CONCLUSIONS: The
use of a fibrin-based sponge showed benefits over the use of fibrin sealant in lung
surgery and liver resection. Less use of health care resources with the application of
fibrin-based sponges versus fibrin sealant resulted in lower associated treatment
costs per patient.
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OBJECTIVES: Earlier research has shown that Hand Eczema (HE) is often work-
related, widespread, potentially disabling and costly, but often misdiagnosed and
mistreated. Severe Chronic Hand Eczema (CHE) can be particularly burdensome,
especially among severe patients refractory to therapy. We assessed cost-of-illness
of severe CHE patients refractory to topical potent corticosteroids and their prev-
alence among HE patients accessing dermatology centres. METHODS: a naturalis-
tic, multicentre study was conducted in 14 Italian dermatology centers. HE patients
aged 18 years, consecutively accessing the participating centers through a
6-month period were enrolled. Socio-demographic and clinical data were collected
for all patients, while direct, indirect costs and HRQol data were collected on severe
refractory CHE patients. HRQoL was collected with the EQ-5D and the condition-
specific Dermatology-Life-Quality-Index (DLQI, having a summary score ranging
from 0 to 30, higher score corresponds to more impaired HRQoL). Direct and indi-
rect costs data were collected through a retrospective 8-week time horizon, using
the societal perspective. RESULTS: in total 981 HE patients were enrolled (mean
ageSD39.115.1, 35.9% male), 11.0% had severe refractory CHE. DLQI meanSD
sum score was 11.36.3. With EQ-5D 96.2% of patients reported moderate or severe
pain/discomfort, 73.1% problems with usual activities, 55.8% anxiety/depression
and 52.9% problems with self-care. VAS meanSD60.423.3. On average hospi-
talizations cost 67.3€/patient-month, travels cost 43.4€/patient-month, specialist
visits cost 41.0€/patient-month, other products (gloves, gauze bandage, vacuum
cleaner, cosmetics) cost 27.2€/patient-month, diagnostic exams cost 19.6€/patient-
month, non pharmacological therapy (emollients, galenic products, soap, UV-ther-
apy) cost 18.7€/patient-month, pharmacological therapy cost 18.2€/patient-month.
Patients lost on average 4.9 workdays/patient-month for reasons attributable to
their disease. CONCLUSIONS: Approximately one tenth of HE patients accessing
dermatology centers have severe refractory CHE. These generate high costs to
manage their condition, and have a significant productivity loss and a poor HRQoL.
An appropriate diagnosis and treatment is necessary to efficiently manage the
disease.
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Cystic fibrosis (CF) is a genetic disease characterized by progressive lung disease. In
the US, the median age of death is 27 years. Published studies of the cost of CF by
severity are outdated and do not report costs stratified jointly by age and FEV1.
OBJECTIVES: To gain understanding of the current economic burden of disease, we
estimated the cost of CF by severity and age group. METHODS: We used an admin-
istrative claims database from a large US health plan to estimate mean annual total
costs for patients with CF by age category (in 5-year increments) for patients ages 5
and older from 2004 to 2008. As claims data do not contain information on FEV1, we
derived the proportions of patients with mild (FEV1 70% predicted), moderate
(40-69% predicted), and severe (40% predicted) CF by age category using data from
the CF Foundation Registry. We then estimated the ratios of costs for moderate and
severe patients relative to mild patients using data from Lieu et al. (1999). Finally,
we estimated treatment costs for patients with CF by age and FEV1 using propor-
tions of patients in each FEV1 category, relationships between cost and disease
severity, and costs by age from the database analysis. RESULTS: Preliminary esti-
mated annual costs of care were $30,000, $57,000, and $215,000 for patients with
mild, moderate, and severe disease, respectively. For all severity groups, costs were
highest among children 10-14 years, and decreased with increasing age through
age 45 years. Estimated annual costs of care for patients with CF ranged from
$15,600 for mild patients aged 40-44 years to $343,900 for severe patients aged 10-14
years. CONCLUSIONS: Annual costs of CF care are highly variable by age and dis-
ease severity. Interventions that keep patients out of the severe disease state may
save costs.
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OBJECTIVES: Current asthma management guidelines are based on the level of
asthma control. This study was designed to estimate quality of life and health care
costs according to the patients’ level of asthma control in France and in Spain in
real-life setting.METHODS:On a 1-month and a 3-months period. An observational
retrospective bottom-up cost of illness study (XX2113553) was conducted simulta-
neously in both countries among adults with asthma. Patients were recruited by
samples of general practitioners during four quarterly waves throughout the year
2010 avoiding thus a seasonal bias. Asthma control was evaluated using the auto-
test Asthma Control Test (ACTTM) for a one month period and 2009 GINA’s asthma
control criteria for a three months period. Quality of life (QoL) was assessed using
EQ-5D profile. Costs (direct and indirect) were evaluated from a societal
perspective. RESULTS: A total of 2671 patients (France: 1154; Spain: 1517) were
enrolled in the survey. Asthma was determined to be well-controlled (ACT  20) in
54.2% [IC 95%: 50.9% - 57.7%] and 58.8% [IC95: 56.2% - 61.3%] of French and Spanish
patients respectively. In both countries, average EQ-5D scores were higher for pa-
tients with well-controlled asthma (France: 0.9 vs. 0.7, p0.0001; Spain: 0.9 vs. 0.6,
p0.0001). Total costs of asthma varied accordingly to asthma control in both
countries. The average total cost (Euros/month/patient) of well-controlled asthma
was 57 € (467) in France and 82 € (171) in Spain compared with 111 € (618)
(p0.0001) and 221 € (323) (p0.0001) respectively for not well-controlled asthma.
Similar variations were observed using the GINA’s criteria on a 3-months period.
CONCLUSIONS: Results suggested that a poor asthma control is associated with
higher costs and lower QoL in patients with asthma in both countries. Improving
the control of asthma could eventually be associated to a decrease of the burden of
asthma.
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OBJECTIVES: To examine the relationship between costs and severity of COPD, and
to up-date the economical burden of COPD for the Swedish society.METHODS: The
study sample was identified in 2009 from earlier clinical examinations of general
population cohorts within the OLIN (Obstructive Lung Disease in Northern Sweden)
studies. A number of 993 subjects were identified as having COPD (GOLD spiromet-
ric criteria). In 2009-2010, telephone interviews on resource utilization were made
to a sample of 244 subjects, stratified by disease severity. Interviews were per-
formed quarterly to minimize the risk of recall bias. Costs were calculated by ap-
plying unit costs from 2010. The prevalence for each disease severity was multi-
plied with the mean costs in order to calculate total societal costs. Non-parametric
tests were used for testing the influence of COPD severity on costs in 2010, and
when comparing the results with a previous study in 1999. RESULTS: A highly
significant relationship was found between disease severity and costs. The mean
A490 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) A 2 3 3 - A 5 1 0
